Navigation Links
Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
Date:8/11/2009

THOUSAND OAKS, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the publication of results from two pivotal Phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk in more than 7,800 women with postmenopausal osteoporosis and in more than 1,400 men with non-metastatic prostate cancer undergoing androgen deprivation therapy (ADT) leading to bone loss. In both studies, published today in The New England Journal of Medicine (NEJM), patients receiving twice-yearly denosumab experienced significant increases in bone mineral density (BMD) compared to placebo, associated with more than 60 percent reduction in vertebral fracture in both patient populations.(1,2) These data were previously reported by Amgen at medical congresses.

To view the Multimedia News Release, go to:http://www.prnewswire.com/mnr/amgen/39203/

"The discovery of the RANK Ligand pathway represents a significant advance in the understanding of bone biology," said Roland Baron, Ph.D., D.D.S., professor and chair of department of Oral Medicine, Infection, and Immunity at the Harvard School of Dental Medicine. "These results demonstrate that targeting the RANK Ligand pathway with denosumab could represent a promising new approach in two different disease settings characterized by bone loss."

FREEDOM Osteoporosis Study Results: Significant Fracture Reduction Seen Across the Skeleton in Postmenopausal Women with Osteoporosis

Results from the FREEDOM (Fracture REduction Evaluation of Denosumab in Osteoporosis every six Months) study, showed that women receiving a subcutaneous shot of d
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
4. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
5. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
8. Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies
9. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
10. Studies Show Body Mass Index Has No Effect on Resolution and Healing of GERD Symptoms
11. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... for Vidaza versus 26.2 for ... patients on Vidaza compared to ... compared to conventional ... Only epigenetic modifier to show survival benefit in cancer Stratified log-rank p-value = ...
... trial of AKIi-5 as the first human clinical study ... involving the systemic ... Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company focused on discovering ... positive results from preclinical efficacy studies for its,proprietary systemically-administered, ...
Cached Medicine Technology:Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 2Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 3Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 4Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 5Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 6Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 7Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS) 8Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4
(Date:7/11/2014)... Cancer researchers in Slovenia say genetic ... on how patients respond to treatment with pemetrexed (Alimta), ... has the full story. Click here to read ... University of Ljubljana and the Ljubljana Institute of Oncology ... types of polymorphisms. They found that patients with genetic ...
(Date:7/11/2014)... 11, 2014 Anterior Cruciate Ligament (ACL) ... the type of material used to create a new ... game, say researchers presenting their work today at the ... Medicine ( AOSSM ). , “Our study ... (tissue harvested from a donor) fail more frequently than ...
(Date:7/11/2014)... Woodland Hills permanent teeth in one day ... Art Institute in Woodland Hills and Oxnard, Calif., will speak ... Del Rey, Calif. , The award-winning prosthodontist, international speaker ... teeth in one day dental procedure at 1:30 p.m. Friday, ... developed 15 years ago, Dr. Jivraj said. Getting new teeth ...
(Date:7/11/2014)... 2014 BellasDress, the experienced dressmaker in ... online suppliers when it comes to beach wedding ... collection of beach wedding outfits in its online shop. ... elegant outfits. , BellasDress has been considered as ... According to the company’s senior spokesman, BellasDress provides superb ...
(Date:7/11/2014)... The International Concussion Organization is hosting its 1st ... in Times Square, New York on July 17th ... that is plaguing athletes in nearly all sports ... Symposium gathers more than a dozen internationally prominent ... legal scholars for engaging and uniquely relevant scientific ...
Breaking Medicine News(10 mins):Health News:New Research Finds Genetic Variables Impact Chemotherapy Response, According to Surviving Mesothelioma 2Health News:ACL Reconstructions May Last Longer With Autografts 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 2Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 3Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 4Health News:Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week 5Health News:BellasDress Emerges As Popular Online Supplier Of 2014 Beach Wedding Dresses 2Health News:The International Concussion Organization 501(c)(3) hosts its 1st Annual Concussion Symposium at the Best Buy Theater in Time Square, NYC, July 17th, 2014. 2
... Ala., May 27 Leading fitness social network and tracking ... name to DailyBurn , effective immediately.In just ... community of more than 125,000 members, who have, depending on ... gained an average of 5.75 lbs of muscle using DailyBurn,s ...
... Integrated Delivery Systems, Telehealth Pioneer ATI is Transforming Care for High-Risk, ... Care 24/7/365 , ... Irvine, Calif., and Minneapolis, Minn. ... now, Entrepreneur magazine named American TeleCare, Inc. (ATI) as one of ...
... HabitsMORRISTOWN, N.J., May 27 Whether it,s "powdering your nose" ... significant amount of time in the bathroom. According to ... minutes each day in the bathroom -- that adds up ... than double that of the average vacation trip(1). And ...
... ignite09 to Improve Health Outcomes and Lower CostsWASHINGTON, ... Consumerism, the American Benefits Council and Hewitt Associates ... are bringing together leaders in innovation from across ... the convergence of behavioral economics and healthcare. ...
... Longer term follow-up indicates modest efficacy in primary ... 27 Ceregene, Inc. today reported additional clinical ... of CERE-120 in 58 patients with advanced Parkinson,s ... deliver the neurotrophic factor, neurturin, to Parkinson,s disease ...
... Practical Insights on Physician Engagement, Career SuccessSCOTTSDALE, Ariz., ... Corporation, whose Fusionfx solution suite aggregates ... single, clinically relevant views of patient information, today ... papers documenting the increasing involvement of healthcare chief ...
Cached Medicine News:Health News:Gyminee Raises 525K and Relaunches as DailyBurn 2Health News:Entrepreneur Magazine Names American TeleCare, Inc. (ATI) One of the Nation's 100 Brilliant Companies to Watch in 10 Hot Industries 2Health News:Entrepreneur Magazine Names American TeleCare, Inc. (ATI) One of the Nation's 100 Brilliant Companies to Watch in 10 Hot Industries 3Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 2Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 3Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 4Health News:Where Do Americans Spend More Than a Week Each Year? Not on Vacation... 5Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 2Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 3Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 4Health News:Key Stakeholders Convene Capitol Hill Symposium To Advance Convergence of Behavioral Economics and Healthcare 5Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 2Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 3Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 4Health News:Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease 5Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 2Health News:Carefx's Newest White Paper Illuminates Healthcare CIOs' Growing Role in Operations, Strategic Thinking and IT Project Decision Making 3
The Aaron 800-EU is designed and engineered to be the most reliable and durable desiccator available today....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: